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Abstract
Since the identification of BRCA1 there has only ever been described two bi-allelic mutation carriers, one of whom was
subsequently shown to be a mono-allelic carrier. The second patient diagnosed with two BRCA1 mutations appears to
be accurate but there remain some questions about the missense variant identified in that patient.
In this report we have identified a woman who is a bi-allelic mutation carrier of BRCA1 and provide an explanation as
to why this patient has a phenotype very similar to that of any mono-allelic mutation carrier. The splice variant
identified in this patient appears to be associated with the up-regulation of a BRCA1 splice variant that rescues the
lethality of being a double mutant.
The consequences of the findings of this report may have implications for mutation interpretation and that could serve as
a model for not only BRCA1 but also for other autosomal dominant disorders that are considered as being embryonically
lethal.
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Introduction
There have been a considerable number of mutations iden-
tified in BRCA1 since its identification in 1994 [1]. During
this time in excess of 15,000 BRCA1 variants have been
submitted to the National Human Genome Research
Institute (NHGRI)-supported Breast Cancer Information
Core (http://research.nhgri.nih.gov/bic/) database. Patients
harbouring a deleterious change in BRCA1 have a signifi-
cantly increased risk of developing breast and or ovarian
cancer [2]. Nonsense mutations represent the majority of
unequivocal deleterious mutations in BRCA1 [3]. Currently,
much attention has been focused on insertion/deletion
mutations, missense mutations and intron-exon boundary
changes since these are more difficult to classify with
respect to their pathogenicity. Recent advances in the clas-
sification of these types of alteration via the development of
algorithms have significantly helped in defining pathogen-
icity, but it remains difficult to accurately and rapidly clas-
sify all of the variants that have been identified to date [4].
Since the identification of BRCA1 much has been learned
about its function, but one of the earliest findings was the
paucity of bi-allelic mutations in founder populations [5, 6]
and in mouse models of disease, where colonies of hetero-
zygote Brca1 mice never produced any viable homozygous
mutant offspring [7]. Collectively, this information implied
that bi-allelic BRCA1 mutations were embryonically lethal.
This is in contrast to bi-allelic BRCA2 mutation carriers
who do survive but invariably develop Fanconi anemia [8].
There have been two reports of patients with bi-allelic
mutation in BRCA1 [6, 9]. The report by Boyd et al. [9] of a
woman who was apparently a homozygous carrier of a
c.2800delAA has since been shown to be a PCR artefact
where preferential amplification on one allele masked the
presence of the other [10]. The more recent report by
Domchek et al. [6] of a developmentally delayed patient
with short stature and an ovarian cancer diagnosed at
28 years of age, an unusual age even for a BRCA1 mutation
carrier, appears to be the first confirmed report of a patient
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with two BRCA1 mutations in trans. One mutation in this
patient is unequivocally causative, a c.2576delC change
residing in exon 11 and a missense change c.5207 T >C
(Val1736Ala) located in exon 20. The Val1736Ala missense
variant has been subjected to an extensive battery of tests
that includes in silico analysis in conjunction with segrega-
tion and functional analysis, which clearly indicate its
pathogenicity. However, there remains some questions
about the pathogenicity of Val1736Ala, as logistic regres-
sion modelling suggests otherwise [11] and it is not known
what, if any, residual function can be associated with the
variant. This raises the possibility that the missense variant
may retain function and that other factors may be involved
that are not related to BRCA1 that may have led to her
early demise. The more recent report by Sawyer et al. [12]
highlighted a patient with the same developmental delay
and diagnosis of breast cancer at 23 years of age. This
patient harboured one unequivocally causative mutation,
c.594_597del (p.Ser198Argfs*35) and another missense
mutation on exon 18 (c.5095C>T; p.Arg1699Trp) that has
previously been reported to be pathogenic and confers
increased risk to breast and ovarian cancers [13]. This
patient, however, was deduced to have a subtype of FA.
We herein report on a woman who developed breast
cancer at an early age with no developmental delay who
was referred to our laboratory for genetic testing and subse-
quent follow-up studies since she was shown to harbouran
unequivocal BRCA1 mutation and a splice site mutation in
trans, both of which are predicted to result in the absence
of functional full-length wildtype BRCA1.
Methods
This study was approved by the institutional review
board of the Hunter New England Health service.
DNA Extraction
DNA was extracted from peripheral whole blood by salt
extraction.
BRCA1 Mutation Analysis
The entire coding sequence including the intron-exon
boundaries of BRCA1 was amplified using primer sequences
design in the laboratory. The PCR reactions were treated
with ExoSAP (Thermo Fisher Scientific) prior to being bi-
directionally sequenced with the BigDye® Terminator v3.1
Cycle Sequencing Kit and capillary-electrophoretically sepa-
rated using an ABI3730 DNA Analyzer automated sequen-
cer (Applied Biosystems). Sequencing traces were analysed
using Mutation Surveyor v3.24 (SoftGenetics®). Mutations
were described using the nomenclature guidelines of the
Human Genome Variation Society (http://www.hgvs.org).
The DNA sequence numbering is based on the cDNA
sequences for BRCA1 (NM_007294.3).
RNA Extraction
Lymphocytes isolated from the patients were infected with
Epstein-Barr virus (EBV) to establish the immortal lympho-
blastoid cell lines (LCLs). These LCLs were maintained in
RPMI media (Thermo Scientific) supplemented with 10 %
fetal calf serum (Sigma-Aldrich) in an incubator set to 37 °C
and 5 % CO2. Puromycin (InvivoGen) was added to the
EBV cells to prevent RNA degradation by nonsense-
mediated decay (NMD).
Total RNA was isolated from cells of carrier patients
using Trizol® (InvitrogenTM) according to the protocol
provided by the manufacturer. RNA was reverse tran-
scribed to cDNA using SuperScript™ II reverse transcriptase
(Invitrogen™) according to the protocol provided by the
manufacturer.
Sequencing of BRCA1 isoforms
Primers were designed to flank the region of interest
(Invitrogen™). One forward primer (5′-TGAGAACTCT
GAGGACAAAGCA-3′) is located in exon 8 and the
other (5′-CTGAAGATACCGTTAATAAGGCA-3′) is
located in exon 9. The reverse primer (5′-CCCTGATA
CTTTCTGGATGC) is located in exon 11. Polymerase
chain reaction (PCR) was conducted under the following
cycling conditions: denaturation at 95 °C for 5 min; 32 cy-
cles of 95 °C for 30 s, 59 °C for 40 s and 72 °C for 40, and
extension at 72 °C for 10 min. The PCR products were then
size-separated by electrophoresis on a 2 % agarose gel.
Direct sequence analysis was performed using the
BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems) and size separated by capillary-electrophoresis
using an ABI3730 DNA Analyzer (Applied Biosystems).
Sequencing traces were analysed using Mutation Surveyor
v3.24 (SoftGenetics®).
Real-time analysis of BRCA1 isoforms
Real-time PCR was performed using SYBR® Green PCR
amplification on an Applied Biosystems ABI PRISM®
7900HT Sequence Detection System (SDS). A 12.5 μl re-
action volume was set up, which included 6.25 μl SYBR®
Green PCR MasterMix, 0.25 μl B-actin (housekeeping
gene) or custom BRCA1 forward and reverse primers
(5 μM) (Table 1), and 0.625 μl reverse transcription
product from the patient and two controls. All reactions
were run in triplicate. The reactions were incubated at
50 °C for 2 min and 95 °C for 10 min, followed by 40 cy-
cles of 95 °C for 15 s and 60 °C for 1 min. The results
were analysed using the SDS software.
Results
The patient presented with breast cancer at 30 years of
age without any immediate family history (pedigree
shown in Fig. 1). The tumour was defined as being es-
trogen, progesterone and HER2 receptor negative, and
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thus suggesting that due to her young age she was likely
to have a genetic predisposition to early onset disease.
Genetic testing of DNA derived from her peripheral
blood lymphocytes revealed a frameshift mutation in
exon 11 of BRCA1 (c.2681_2682delAA) and a splice site
change located in intron 9 that results in the absence of
exon 10. This splice site change, c.594-2A > C, is pre-
dicted to be a splice site mutation that causes a frame-
shift, resulting in a premature stop codon). Genetic
testing of the mother revealed that she carried the
c.2681_2682delAA mutation and the father the c.594-
2A > C splice site variant. The BRCA1 exon 11 mutation
is clearly pathogenic and is associated with an increased
risk of early onset breast and/or ovarian cancer. The
presence of two potentially pathogenic mutations in
trans observed in a single individual appears to be con-
trary to the evidence provided by animal models and
founder populations where BRCA1 mutations in trans
are either embryonically lethal or unreported [6, 7]. The
presence of a splice site mutation does not automatically
infer that splicing is affected, so to ensure that splicing
was indeed interrupted we designed a series of primers
to interrogate the expression of the allele that carried
the splice site variant. Primers located in exon 8 and
exon 11 were used to identify which transcripts were
present in the cDNA of the proband compared to a healthy
control subject. The primer used in exon 11 was 5′ of the
c.2681_2682del mutation and as such is referred to as the
“wildtype” allele. The results revealed the presence of three
transcripts, the “wildtype” transcript, the exon 10-deleted
(Δ10) transcript and a commonly occurring isoform with
exons 9 and 10 deleted (Δ9/10) transcript (Fig. 2). In the
healthy control subject only the wildtype and Δ9/10 tran-
script can be identified, confirming the specificity of the
exon 10 deletion in the proband.
The paternal allele carries a c.641G polymorphism in
exon 10 (Gly214) which is in linkage disequilibrium
with the c.594-2A > C mutation. If read-through of the
splicing variant was occurring, the allele produced
would lead to the translation of a functional BRCA pro-
tein. To determine whether this allele was expressed, a
PCR was performed using primers which annealed to
exon 9 and exon 11 (5′ of the maternal mutation). The
amplified fragment would exclude the 9/10del isoform
but would include exon 10 of the maternal allele as well
as the paternal allele if present. If this fragment was
heterozygous for the 641A > G polymorphism it would
indicate that exon 10 of the paternal allele was present,
indicating that the c.594-2A > C mutation is not fully
penetrant.
Our results revealed that only the maternal wildtype
allele was expressed and that no paternal allele could be
detected (Fig. 2). This result confirmed that the c.594-
2A > C did affect the expression of the paternal allele,
thus the functional BRCA1 (Δ9/10) trranscript must be
produced from an alternatively-spliced isoform.
Fig. 1 Pedigree of the family. Mutations present in this family are stated below the symbols of the individuals tested
Table 1 Sequences of forward and reverse primers used for the detection of expression of BRCA1 isoforms by RT-PCR
Isoform Forward sequence Reverse sequence
Wildtype BRCA1 (does not cover truncation in exon 11) 5′-GCAACTTATTGCAGTGTGGG-3′ 5′-ACAAGCAGCCTTTTTTGCAG-3′
Exon 10 deleted (Δ10) 5′- GCAACTTATTGCAGCTGCTTG-3′ 5′- AGCTGCACGCTTCTCAGTG-3′
Exon 9 and 10 deleted (Δ9/10) 5′- GTCTGTCTACATTGAATTGGCTG-3′ 5′- AGCTGCACGCTTCTCAGTG-3′
Exon 11q deleted (Δ11q) [12] 5′-CCAACTCTCTAACCTTGGAACTGTG-3′ 5′-GATGACCTTTCCACTCCTGGTTC-3′
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Since the maternal and paternal alleles are not expressed
as a result of the respective mutations they carry, the
question arises as to what is occurring in the proband that
has allowed her to survive and present with a phenotype
that is similar, to a women harbouring a single deleterious
change in BRCA1. We aimed to determine whether one
or more isoforms of BRCA1 could rescue the phenotype
such that a functional BRCA1 transcript was produced
but not of full length (Fig. 3). For this analysis we used
real-time polymerase chain reaction (RT-PCR) to quantify
the levels of transcripts present in the proband and a
series of control subjects (see Fig. 4). Primers were de-
signed to specifically capture the expression levels of the
Δ10 transcript, as well as the Δ9/10 isoform and another
functional exon 11q-deleted (Δ11q) isoform [14]. Both the
Δ9/10 isoform and the Δ11q isoforms are in-frame and
have potential residual functional activity. We compared
the results from the proband against a normal control and
a second breast cancer patient who harboured a mutation
in one allele that resulted in the deletion of exon 10
(c.581C > T;p.Ala194Val). The results revealed that in the
control subject expression of the Δ9/10 isoform is detect-
able at approximately the same level as the wildtype
BRCA1 transcript. There is also expression of the Δ9/10
isoform that is similar to wildtype BRCA1 expression
levels in the breast cancer patient control (heterozygous
mutation carrier). In both of these subjects, the Δ11q iso-
form and the Δ10 isoform (specific to the proband) were
not detectable. The Δ9/10 isoform was substantially up-
regulated by about 2.5-fold relative to the levels of the
BRCA1 “wildtype” transcript in the proband. The Δ10
transcript was observed to be expressed at approximately
similar levels to the “wildtype” transcript, and we also
showed the expression of the Δ11q isoform. This collective
observations suggest that the Δ9/10 isoform and the Δ11q
isoform is upregulated in the proband compared to that
observed in the control subject and another breast cancer
patient control.
Discussion
There is a paucity of patients harbouring BRCA1 muta-
tions in trans, which is considered to be due to the
embryonically-lethal nature of these events. Epidemio-
logical evidence in founder populations and animal
models support this view and to date only one example
of a patient harbouring two mutations in trans has been
reported [6]. Even though the report from Domchek et
al. (2012) is comprehensive in its assessment of the mis-
sense change there remain some questions about the re-
ported patient. Given the developmental delay, short
stature and microcephaly observed in the patient re-
ported by Domchek et al. (2012), it remains to be deter-
mined if there were other genetic alterations that could
give rise to the patient’s severe symptoms. And like this
previous report, a more recent one by Sawyer et al.
(2015) [12] showed a patient with biallelic BRCA1 muta-
tions in trans with a similar phenotype.
Like the splice site mutation in our proband, there
is a possibility that the missense Val1736Ala and the
Arg1699Trp mutations possibly retain some function, as
the two probands harbouring the missense and nonsense
mutations in trans have a low age of cancer onset even for
monoallelic BRCA1 mutation carriers [6]. Nevertheless,
these patients harboured an unequivocal BRCA1 mutation
and a variation of unknown functional significance that is
very likely to be pathogenic. The difference between this
Fig. 2 Analysis of the BRCA1 mutation c.594-2 A > C by agarose gel electrophoresis. PCR products amplified using primers specific for exon 8 and exon
11 of the BRCA1 gene. P is the patient sample and C is the control sample. Puromycin treated (P+) and puromycin non-treated (P −) are indicated in the
figure. M is the 100 bp DNA ladder (Promega). Three different transcripts are present in the proband (P) representing a wildtype fragment, a fragment
lacking exon 10 and a fragment representing the Δ9/10 isoform Only the wildtype fragment and the Δ9/10 isoform are present in the control sample (C)
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Fig. 3 Analysis of the BRCA1 variant c.641A>G. a Agarose gel showing PCR products amplified using primers specific for exon 9 and exon 11 of
the BRCA1 gene. P is the patient sample while C is the control sample. Puromycin treated (+) and puromycin non-treated (-) are indicated in the
figure. M is the 100bp ladder size marker (Promega). The band at 228bp represents the fragment amplified from exon 9 to exon 11 and includes
exon 10. The band at 151bp represents the fragment lacking exon 10. b Sequencing analysis of the 228bp band for the patient indicates the
presence of the c.641A allele (arrow), but not c.641G. c Sequencing of the 228bp band for the control sample indicates the presence of the
c.641A allele
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patient and the one reported herein is that there appears to
be a rescue of the phenotype by virtue of the fact that a
functional isoform is upregulated on the allele harbouring
the c.594-2A>C variant. The functional isoform is linked to
the presence of the intronic splice site mutation adjacent
to exon 10. This alteration results in the loss of exon 10
and concomitantly activates a known isoform that appears
to be similar in function to the wildtype allele [15]. In
support of this, we were fortunate enough to encounter
another unrelated patient who harboured a single mu-
tation at the 3’ end of exon 9 (c.581C>T, p.Ala194Val),
also predicted to result in alternate splicing. Interestingly,
in this patient it was observed that the Δ9/10 isoform was
also upregulated but not to the same extent as that ob-
served in the proband reported herein. It has been re-
ported that the c.594-2A>C variant is not associated with a
highly-penetrant disease profile even though the allele is
not expressed in persons who harbour this change [16]. It
is likely that as this variant has been detected in trans with
other unequivocally pathogenic mutations, such as the
truncating c.2681_2682del in our patient and the BRCA1
founder variant exon13ins6kb [16], the pathogenicity of
this variant has not been until now fully elucidated but
has been the subject of investigation [17]. We have
unequivocally shown that the BRCA1 c.594-2A>C variant
results in a loss of the full-length wildtype allele and the
upregulation of a functional BRCA1 isoform. This is, to
our knowledge, the first evidence demonstrating the
functional activity of the Δ9/10 BRCA1 isoform. Segrega-
tion analysis of families harbouring this variant clearly indi-
cates reduced penetrance that is at odds with expression
data which unequivocally shows the absence of the allele-
specific transcript [18]. In the absence of any other infor-
mation this would create a conundrum in terms of what it
meant to harbour this change. The data from the proband
suggests there is a feedback loop associated with the splice
site mutation and the expression of the Δ9/10 isoform that
results in the rescue of the phenotype, which is consistent
with the report from Dosil et al. (2010) who characterised
the role of the splice variant c.591C>T in the generation of
the Δ9/10 isoform [19]. Taken together, result explains the
significantly reduced disease penetrance observed in
mono-allelic carriers of the c.594-2A>C variant.
Conclusion
We have an example of a true biallelic mutation in
BRCA1, both of which significantly alter the full-length
transcripts of BRCA1. However, as a result of upregulation
of the Δ9/10 functional isoform rescue of the phenotype
occurs. Without the compensation of the Δ9/10 isoform it
is likely that either the patient would have not developed
in utero or would have had severe mental retardation.
This implies that the Δ9/10 isoform is functional and
capable of orchestrating most, if not all, of the function of
the wildtype allele. Acknowledgement of this finding will
make genetic analysis and counselling issues more
Fig. 4 Relative expression (2-ΔΔCT) of each of the BRCA1 isoforms compared to the wildtype BRCA1 in patient and controls. The BRCA1 Δ10 and
Δ11q isoforms are not present in any of the two controls
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complex since mutations occurring in region of exons 9
and 10 of BRCA1 may not result in predicted outcomes
based on sequence analysis alone.
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